IL1B and pancreatic neoplasm: Mitsunaga et al. [48] assessed the prognostic value of IL-6 and IL-1β in patients with pancreatic cancer receiving gemcitabine, and using multivariate analysis they found that high IL-6/high IL-1β levels were an independent prognostic factor for poor OS (HR = 2.10) and short PFS (HR = 2.32).